Rotterdam, 3014 DA,
Netherlands
Centrient Pharmaceuticals ( ex DSM Sinochem Pharmaceuticals ) Technographics
Centrient Pharmaceuticals ( ex DSM Sinochem Pharmaceuticals ) Technographics, Software Purchases, AI and Digital Transformation Initiatives
Discover the latest software purchases and digital transformation initiatives being undertaken by Centrient Pharmaceuticals ( ex DSM Sinochem Pharmaceuticals ) and its business and technology executives. Each quarter our research team identifies on-prem and cloud applications that are being used by the 2000 Centrient Pharmaceuticals ( ex DSM Sinochem Pharmaceuticals ) employees from the public (Press Releases, Customer References, Testimonials, Case Studies and Success Stories) and proprietary sources.
During our research, we have identified that Centrient Pharmaceuticals ( ex DSM Sinochem Pharmaceuticals ) has purchased the following applications: Microsoft 365 for Collaboration in 2015, Microsoft Azure Cloud Services for Application Hosting and Computing Services in 2014, Mimecast Email Security for Secure Email Gateways (SEGs) in 2019 and the related IT decision-makers and key stakeholders.
Our database provides customer insight and contextual information on which enterprise applications and software systems Centrient Pharmaceuticals ( ex DSM Sinochem Pharmaceuticals ) is running and its propensity to invest more and deepen its relationship with Microsoft , Cato Networks , Mimecast or identify new suppliers as part of their overall Digital and IT transformation projects to stay competitive, fend off threats from disruptive forces, or comply with internal mandates to improve overall enterprise efficiency.
We have been analyzing Centrient Pharmaceuticals ( ex DSM Sinochem Pharmaceuticals ) revenues, which have grown to $498.0 million in 2024, plus its IT budget and roadmap, cloud software purchases, aggregating massive amounts of data points that form the basis of our forecast assumptions for Centrient Pharmaceuticals ( ex DSM Sinochem Pharmaceuticals ) intention to invest in emerging technologies such as AI, Machine Learning, IoT, Blockchain, Autonomous Database or in cloud-based ERP, HCM, CRM, EPM, Procurement or Treasury applications.
Centrient Pharmaceuticals ( ex DSM Sinochem Pharmaceuticals ) Tech Stack and Enterprise Applications
Centrient Pharmaceuticals ( ex DSM Sinochem Pharmaceuticals ) Collaboration
Vendor |
Previous System |
Application |
Category |
Market |
VAR/SI |
When |
Live |
Insight |
|---|---|---|---|---|---|---|---|---|
| Microsoft | Legacy | Microsoft 365 | Collaboration | Collaboration | n/a | 2015 | 2015 |
In 2015, Centrient Pharmaceuticals implemented Microsoft 365 as its Collaboration platform. The implementation served the company wide employee base of about 2000, establishing Microsoft 365 as the primary environment for email, document collaboration, and internal communications.
Microsoft 365 was deployed as a cloud first tenant providing standard Collaboration capabilities, including Exchange Online for email, SharePoint Online for document management, Microsoft Teams for real time collaboration, and OneDrive for Business for endpoint file sync, and the company is using Microsoft 365 on their website. The deployment centralized collaboration workflows and standardized document storage and sharing across corporate functions, with tenant level identity and access governance aligned to Microsoft 365 operational patterns.
|
Centrient Pharmaceuticals ( ex DSM Sinochem Pharmaceuticals ) IaaS
Vendor |
Previous System |
Application |
Category |
Market |
VAR/SI |
When |
Live |
Insight |
|---|---|---|---|---|---|---|---|---|
| Microsoft | Legacy | Microsoft Azure Cloud Services | Application Hosting and Computing Services | IaaS | n/a | 2014 | 2014 |
In 2014, Centrient Pharmaceuticals, formerly DSM Sinochem Pharmaceuticals, implemented Microsoft Azure Cloud Services. The deployment used Microsoft Azure Cloud Services for Application Hosting and Computing Services to host the companys public-facing corporate website and associated application workloads, establishing a cloud native hosting plane for web content delivery and application compute.
The implementation organized typical application hosting components, including cloud compute for application processes, object style storage for site assets, and network routing for public traffic. Configuration management and automated provisioning workflows were applied to separate staging and production environments, and the Microsoft Azure Cloud Services deployment supported scalable hosting models and standard operational automation consistent with Application Hosting and Computing Services.
Operational coverage centered on the corporate website and supporting IT and digital communications functions, with central IT responsible for environment provisioning and runtime operations. The Microsoft Azure Cloud Services instance served as the primary application hosting layer for web delivery, integrating directly with the companys site infrastructure as indicated by site source references.
Governance emphasized centralized change control, monitoring, and incident response for the hosted environments, aligning application lifecycle processes with cloud provisioning and operational monitoring practices. Security controls and access management were incorporated into the cloud hosting model to support ongoing IT operations under the Application Hosting and Computing Services framework.
|
|
|
|
|
SD-WAN | IaaS |
|
2017 | 2018 |
|
Centrient Pharmaceuticals ( ex DSM Sinochem Pharmaceuticals ) CyberSecurity
Vendor |
Previous System |
Application |
Category |
Market |
VAR/SI |
When |
Live |
Insight |
|---|---|---|---|---|---|---|---|---|
| Mimecast | Legacy | Mimecast Email Security | Secure Email Gateways (SEGs) | CyberSecurity | n/a | 2019 | 2019 |
In 2019, Centrient Pharmaceuticals deployed Mimecast Email Security to protect its corporate email environment. Mimecast Email Security was adopted as the company’s Secure Email Gateways (SEGs) solution, providing perimeter control for enterprise email used by approximately 2,000 employees across the organization.
The implementation centers on standard Secure Email Gateways (SEGs) capabilities, including inbound and outbound email filtering, anti-spam and anti-malware controls, URL and attachment protection, impersonation and phishing defenses, policy-based routing, and email continuity. Mimecast Email Security is configured to enforce organization-wide email policies, retention controls, and secure message handling aligned with life sciences information governance requirements.
Deployment is positioned at the email perimeter to inspect mail flows prior to delivery to corporate mailboxes, operating as a centralized email security layer for the company’s corporate communications. The vendor service is evident on the company website, indicating the Mimecast Email Security deployment is active in production and aligned with both external facing and internal mailflows.
Operational ownership is structured around centralized security and IT administration, with policy configuration, quarantine management, and incident response workflows managed through the Mimecast console. The implementation emphasizes governance of email security, policy standardization, and continuity planning for Centrient Pharmaceuticals email operations.
|
IT Decision Makers and Key Stakeholders at Centrient Pharmaceuticals ( ex DSM Sinochem Pharmaceuticals )
| First Name | Last Name | Title | Function | Department | Phone | |
|---|---|---|---|---|---|---|
| No data found | ||||||
Apps Being Evaluated by Centrient Pharmaceuticals ( ex DSM Sinochem Pharmaceuticals ) Executives
| Date | Company | Status | Vendor | Product | Category | Market |
|---|---|---|---|---|---|---|
| No data found | ||||||